Consolidation into a single reportable segment
First written in FY2020-Q1. 8 of 9 entries say "Restated". Latest entry: FY2024-Q3.
10 other companies' latest entry also says "Restated".
- FY2024-Q3RestatedAnnual report
「The group has a single Pharmaceutical Business segment, so this information has been omitted.」
Reporting under a single Pharmaceutical Business segment was reaffirmed. - FY2024-Q2RestatedAnnual report
「The group has a single Pharmaceutical Business segment, so this information has been omitted.」
Reporting under a single Pharmaceutical Business segment was reaffirmed. - FY2023-Q2RestatedAnnual report
「The group has a single Pharmaceutical Business segment, so this information has been omitted.」
Reporting under a single Pharmaceutical Business segment was reaffirmed. - FY2022-Q2RestatedAnnual report
「The group has a single Pharmaceutical Business segment, so this information has been omitted.」
Reporting under a single Pharmaceutical Business segment was reaffirmed. - FY2021-Q1RestatedAnnual report
「The group has a single Pharmaceutical Business segment, so this information has been omitted.」
Reporting under a single Pharmaceutical Business segment was reaffirmed. - FY2020RestatedAnnual report
「The group had previously been divided into the Pharmaceutical Business and the Medical and Research Equipment Business, but from the current consolidated fiscal year it has been changed to a single Pharmaceutical Business segment.」
The annual report also confirmed the change to a single Pharmaceutical Business segment. The decision was based on the limited significance of the Medical and Research Equipment Business and the determination to view business development, resource allocation and the management structure on an integrated basis. - FY2020-Q3RestatedAnnual report
「The group had previously been divided into the Pharmaceutical Business and the Medical and Research Equipment Business, but from the first-quarter consolidated accounting period it has been changed to a single Pharmaceutical Business segment.」
The change to the Pharmaceutical Business as a single reportable segment was reaffirmed. - FY2020-Q2RestatedAnnual report
「The group had previously been divided into the Pharmaceutical Business and the Medical and Research Equipment Business, but from the first-quarter consolidated accounting period it has been changed to a single Pharmaceutical Business segment.」
The change to the Pharmaceutical Business as a single reportable segment was reaffirmed. - FY2020-Q1First statedAnnual report
「The group had previously been divided into the Pharmaceutical Business and the Medical and Research Equipment Business, but from the current first-quarter consolidated accounting period it has been changed to a single Pharmaceutical Business segment. This change was made because the Medical and Research Equipment Business was not material in terms of revenue and profit, and because the group determined that it was appropriate to view the Pharmaceutical Business and the Medical and Research Equipment Business as an integrated business from the perspectives of business development, allocation of management resources and the actual management control structure.」
From the first quarter of fiscal 2019, the company abolished the previous distinction between the Pharmaceutical Business and the Medical and Research Equipment Business and changed to a single Pharmaceutical Business segment. The reasons given were the limited significance of the Medical and Research Equipment Business in terms of revenue and profit, and the decision to view business development, resource allocation and the management structure on an integrated basis.